Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Income from Continuing Operations rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.96% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Income from Continuing Operations is -$35.3 million, which was down 23.04% from -$28.7 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Income from Continuing Operations high stood at $1.9 billion for Q2 2024, and its period low was -$92.0 million during Q4 2023.
  • For the 3-year period, Inhibrx Biosciences' Income from Continuing Operations averaged around $138.8 million, with its median value being -$45.9 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 3,898.37% in 2024, then slumped by 101.54% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Income from Continuing Operations (Quarterly) stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 19.62% to -$35.3 million in 2025.
  • Its Income from Continuing Operations stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.